Lybrido

THE ALETTA CLINICAL STUDY: DESIGN OF A RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF LYBRIDO™ IN PREMENOPAUSAL WOMEN WITH ACQUIRED FSIAD (2023) Objectives: Low sexual desire is the most common sexual complaint in women. As a result, many women...

https://finance.yahoo.com/news/freya-pharma-solutions-extends-scientific-102200225.html AMSTERDAM, Feb. 10, 2023 /PRNewswire/ -- Freya Pharma Solutions, a late clinical-stage company focusing on the development of effective pharmaceutical therapies for women diagnosed with Female Sexual...

https://www.pharmaceutical-technology.com/news/female-sexual-interest-drug-reaches-tipping-point-with-phase-iii-plans/ Freya Pharma has received EMA guidance to take its pill Lybrido into Phase III trials to treat female sexual interest disorder. After more than a decade in development, Freya...